67990-66-3

Usage

Uses

N-(2-Amino-4-chlorophenyl)anthranilic acid may be used in chemical synthesis studies.

InChI:InChI=1/C13H11ClN2O2/c14-8-5-6-12(10(15)7-8)16-11-4-2-1-3-9(11)13(17)18/h1-7,16H,15H2,(H,17,18)

Upstream product

• 118-92-3 anthranilic acid 
• 345-18-6 2-fluoro-5-chloronitrobenzene 
• 118-91-2 ortho-chlorobenzoic acid 
• 539-03-7 N-(4-chlorophenyl)acetamide 
• 106-47-8 4-chloro-aniline 
• 88-67-5 2-Iodobenzoic acid 
• 552-16-9 ortho-nitrobenzoic acid 
• 88-72-2 1-methyl-2-nitrobenzene 
• 108-88-3 toluene 
• 89-63-4 4-Chloro-2-nitroaniline 
• 881-51-6 N-(4-chloro-2-nitrophenyl)-acetamide 
• 89-61-2 2,5-dichloronitrobenzene 
• 41513-04-6 2-chloro-5-bromonitrobenzene 
• 60091-87-4 2-(4-Chlor-2-nitrophenyl)aminobenzencarbonsaeure 

Downstream Products

• 50892-62-1 8-chloro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 
• 1024010-08-9 ethyl 4-(8-chloro-5H-dibenzo[b,e][1,4]diazepin-11-yl)benzoate 
• 50373-22-3 8,11-dichloro-5H-dibenzo[b,e][1,4]-diazepine 
• 98374-55-1 8-Chlor-5,10-dihydro-5--11H-dibenzo<1,4>-diazepin-11-on-hydrochlorid 
• 98374-71-1 8-Chlor-5,10-dihydro-5-<<4-(3,4,5-trimethoxybenzoy)-1-piperazinyl>acetyl>-11H-dibenzo<1,4>diazepin-11-on 
• 98374-54-0 8-Chlor-5,10-dihydro-5--11H-dibenzo<1,4>-diazepin-11-on 
• 98374-72-2 8-Chlor-5,10-dihydro-5-<<4-(3,4,5-trimethoxybenzoy)-1-piperazinyl>acetyl>-11H-dibenzo<1,4>diazepin-11-on-hydrochlorid 
• 182679-33-0 2-[4-chloro-2-(3-phenylureido)phenylamino]benzamide 
• 182679-34-1 2-[4-chloro-2-(3-phenylpropionylamino)phenylamino]benzamide 
• 76443-18-0 2-(2-amino-4-chlorophenylamino)benzamide 

Relevant academic research and scientific papers

Clozapine intermediate as well as synthesis method and application thereof (by machine translation)

The invention discloses a clozapine intermediate and a synthesis method and application thereof, and belongs to the technical field of drug synthesis. The synthesis method comprises 1) synthesis of 2 - [(2 - amino -4 - chlorophenyl) amino] benzoic acid, 2) 8 - chlorine -5, 10 - dihydro - 111111H-dibenzo [b, e] [1, 4]-diazepine -11 - ketone. The synthesis method of the clozapine intermediate is simple in preparation process, recyclable in solvent, easy to operate and control, good in color, good in quality, high in purity and high in yield, can be directly used for production and use, and has good practicability. (by machine translation)

Synthesis and pharmacological evaluation of 11-(1,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-5H-dibenzo[b,e][1,4]diazepines with clozapine-like receptor occupancy at dopamine D1/D2 receptor

Clozapine-like compound without agranulocytosis risk is need to cure the treatment resistant schizophrenia (TRS). We discovered (S)-3 as Clozapine-like dopamine D2/D1 receptor selectivity and improved reactive metabolites formation profile by the modification of piperazine moiety in Clozapine. The optimization of (S)-3 gave compound 5 to be best compound (approximately 10-fold stronger affinity for D2/D1 receptor and similar D2/D1 selectivity ratio with Clozapine). Clozapine-like D2/D1 receptor occupancy profile was proved by in vivo evaluation. In addition, the reactive metabolites derived agranulocytosis risk of compound 5 was considered to be lower than Clozapine. The pharmacology detail of compound 5 is being investigated to develop it for TRS treatment.

NOVEL and IMPROVED SYNTHESIS OF ANTIPSYCHOTIC DRUG

The present invention relates to novel as well as improved process for the preparation of Clozapine of Formula I which involves anti-narcotic and highly cost effective raw materials.

Design, synthesis and anticancer activity evaluation of diazepinomicin derivatives

A series of diazepinomicin derivatives were synthesized and evaluated in vitro for their growth inhibitory activity against the human carcinoma cell lines. The results indicated the anticancer selectivity of this kind of compounds. Based on the results, preliminary structure-activity relationships were discussed.

COMPOUNDS WITH 7-MEMBER CYCLE AND THE PHARMACEUTICAL USE THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLISM SYNDROME

The invention discloses a new use of a class of heptacyclic compounds in the preparation of formulations for the prevention and treatment of diabetes and metabolic syndromes; the present invention also discloses a new class of heptacyclic compounds; the present invention also discloses a process for preparing the heptacyclic compounds and a composition containing the same. The heptacyclic compounds of the present invention can be used to effectively preventing or treating diseases such as diabetes and metabolic syndromes.

NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS

The present invention provides compounds according to general Formula (I), a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a prodrug thereof. More particularly, the present invention provides high affinity non-steroidal compounds which are agonists, partial agonists or antagonists of the progesterone receptor.

Synthesis and preliminary pharmacological evaluation of 4′-arylmethyl analogues of clozapine. I - The effect of aromatic substituents

As part of a research program to develop compounds with mixed dopamine D4 and serotonin 5-HT2A antagonist activity with potential for the treatment of schizophrenia, we report a family of compounds based on structural modification of the atypical antipsychotic, clozapine (2). The chemical synthesis, structural characterization and pharmacological evaluation of a series 4′-arylmethyl analogues of clozapine are described. Preliminary receptor binding data are presented, examining primarily the electronic and positional effects of substituents on the introduced arylmethyl group, and secondarily the nature of the aryl ring.